# Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.

> **NCT00958633** · PHASE3 · TERMINATED · sponsor: **University of British Columbia** · enrollment: 237 (actual)

## Conditions studied

- Bipolar I Disorder

## Interventions

- **DRUG:** Escitalopram
- **DRUG:** Bupropion XL

## Key facts

- **NCT ID:** NCT00958633
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-05-20
- **Target enrollment:** 237 (ACTUAL)
- **Why stopped:** Recruitment was stopped before the planned sample size was reached owing to the Covid-19 pandemic and expiration of funding.
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00958633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00958633, "Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT00958633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*